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that the treatmentwith aspirin and5-FUdidnot cause toxicity after
48h exposurewhichmay explain the lack of SSAT response to these
drugs.
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A steady upward trend in the mortality rates from cirrhosis in
the UK has been observed in recent years and in particular in Scot-
land. The liver has a huge regenerative capacity but early diagnosis
is essential. Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of liver disease in the developed world mirroring
the global epidemic of Type 2 diabetes and obesity.
This work aims to determine if Insulin-like growth factor bind-
ing protein-5 (IGFBP-5) would be a suitable biomarker for the
detection of NAFLD. It has already been shown to be upregulated
in skin ﬁbrosis (Yasuoka et al., 2006a) and in ﬁbrosis of the lung
(Yasuoka et al., 2006b). Also, its expression enhances the survival
of hepatic stellate cells and myoﬁbroblasts and the expression of
proﬁbrotic genes (Sokolovic et al., 2010)
The University of Edinburgh have developed a model of NAFLD
in vitro using C3A cells (Filippi et al., 2004), a clonal derivative
of the human hepatoblastoma-based HepG2 cell line. The model
utilised two methods to induce lipid accumulation in cell lines. In
the ﬁrst, cells were treated with lactate, pyruvate, octanoate and
NH4Cl (LPON) for up to 7 days in culture, and this has been shown
to increase intracellular reactive oxygen species (ROS). Alterna-
tively, lipid accumulation can be induced, without ROS formation,
by the presence of oleate. The lack of ROS formation has been
suggested to be due to the inability of oleate to induce carnitine
palmitoyltransferase-1 (CPT-1) which is essential for the transport
of long chain fatty acids across the mitochondrial membrane for
oxidation (Nakamura et al., 2009). In our experiments, intracel-
lular lipid accumulation was observed by staining cultures with
haematoxylin/oil red O, and IGFBP-5 release into the medium was
measured using an ELISA.
Intracellular accumulation of lipids was observed to increase
over time in culturewith the presence of LPONor oleate in compar-
ison with the controls. In the presence of LPON, IGFBP-5 increased
to 0.3±0.1ng/ml at 7 days, whereas, in the presence of oleate,
IGFBP-5 secreted increased to approximately 0.1ng/ml at 5 and 7
days (Fig. 1). Control levels were below the levels of detection of
the ELISA. The difference in levels of IGFBP-5 may be attributed to
the lack of ROS formation with the presence of oleate. This sug-
gests that IGFBP-5 may be a suitable biomarker for the detection
of NAFLD.
Fig. 1. IGFBP-5 release from C3a cells exposed to LPON or oleate (results are
mean± SEM, n=3).
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Acute depletion of the prion proteinmay abrogate A oligomer
toxicity
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Amyloid-beta1-42 (A) oligomers bind to the prion protein (PrP)
with very high afﬁnity (Balducci et al., 2010; Lauren et al., 2009).
This interaction has been shown to mediate the toxic effects of A
on LTP and synaptic function in vitro (Lauren et al., 2009), and on
certain tests ofmemory in vivo (Gimbel et al., 2010). However, con-
ﬂicting reports exist, where the effects of A have been found to be
independentof PrP (Balducci et al., 2010;Calella et al., 2010;Kessels
et al., 2010). If PrP does mediate A toxicity, it becomes an attrac-
tive new target for therapy in AD. The reasons for the contradictory
ﬁndings are unclear, but in each case, despite somemethodological
differences, the role of PrP has been assessed by comparing A tox-
icity in wild-type and embryonic PrP-null (PrP0/0) mice. The aim of
this study was to examine the role of PrP in mediating A effects
using two experimental paradigms. First, in PrP0/0 mice as above,
and second, using RNAi for acute knockdown of PrP, to model the
effects of a PrP-targeted treatment.
We measured dendritic spine loss induced by injection of
synthetic A oligomers (1M) into the hippocampus, as this is
associated with both memory deﬁcits and loss of LTP. In wild-type
(WT) and PrP0/0 mice, we found that A-mediated spine loss was
independent of PrP in hippocampal slices, and also in vivo, after
injection of A. Spine densitywas equally reduced byA treatment
in WT (n=70 dendrites from 3 separate mice± SEM) and PrP0/0
(n=70 dendrites from 3 separate mice± SEM) mice, in each system
(Fig. 1). However, when PrP was acutely depleted in adult WT mice
using lentivirally-mediated RNAi in the hippocampus, we found
signiﬁcantly less spine loss post A treatment (n=150 dendrites
from 6 separate mice± SEM) than in animals given control virus
and A (n=100 dendrites from 4 separate mice± SEM) (Fig. 1).
